Form 4: Immunocore Holdings Director, William Pao, Awarded Share Options

Director William Pao receives share options for Immunocore Holdings plc.

Summary

• William Pao, a director of Immunocore Holdings plc, was granted share options on May 15, 2025.
• The options give him the right to buy 26,198 ordinary shares at an exercise price of $29.06 per share.
• The options vest on the earlier of May 15, 2026, or the day before the next annual general meeting, contingent on continuous service.
• The options expire on May 14, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of share options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of share options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Granting share options to directors is a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Share option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals routinely use stock options as part of their compensation strategy to attract and retain top talent.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market prices at the time of the grant.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the director.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

Immunocore Holdings, Share Options, Director, William Pao, Equity, Form 4